CLAIM AMENDMENTS

This listing of claims will replace all prior versions and listings of claims in the application:

1.-30. (canceled)

31. (previously presented) A device for transdermal delivery of a compound of the following Formula I:

Formula I



wherein A is hydrogen or deuterium, R is C_{1-6}-alkyl, C_{3-10}-cycloalkyl or phenyl, which may each be substituted with C_{1-3}-alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium and where the C-atom marked with a star "*" is present in the (R)-configuration, and the compound of Formula I is present in a polymer matrix and can be released through the human skin in a dose of 0.5-20 mg per day.

32. (previously presented) A device of claim 31 wherein the device is produced by a process comprising adding a compound of Formula I in free base form to the polymer matrix.

33. (previously presented) A device of claim 31 wherein the polymer matrix incorporates 55-90 percent by weight of a contact adhesive and is self-adhesive.

34. (previously presented) A device of claim 31 wherein the polymer matrix incorporates one or more contact adhesives which are chosen from acrylates, ethylene vinyl acetates (EVA), silicones or styrene block copolymers (SXS).

35. (previously presented) A device of claim 31 wherein the polymer matrix comprises up to 50-95 percent by weight of a hot-meltable mixture of a silicone based contact adhesive and at least one softener.

36. (previously presented) A device according to claim 31 wherein the polymer matrix comprises up to 50-95 percent by weight from (a) a hydrophilic contact adhesive and/or (b) a mixture of a hydrophobic contact adhesive with 2-20 percent by weight, based on the total weight of the polymer matrix, of a hydrophilic polymer and/or (c) a mixture of a hydrophilic with a hydrophobic contact adhesive.

37. (previously presented) A device according to claim 36 whereby the hydrophilic polymer is PEO, PVP or PVAc.

38. (previously presented) A device of claim 31 wherein R is methyl, ethyl, isopropyl, 1-propyl, 1-butyl, 2-butyl, tertiary-butyl, iso-butyl, pentyl or hexyl.

39. (previously presented) A device of claim 31 wherein the compound is (R)-2-[3-(1,1-diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate

(fesoterodine).

40. (previously presented) A device of claim 31 wherein the compound of the Formula I has been introduced into the polymer matrix in a degree of purity of above 97 percent by weight.

41. (previously presented) A device of claim 31 wherein the device:

(a) exhibits a surface of a maximum 50 cm^2;

(b) comprises a self-adhesive polymer layer, which

(b1) exhibits a weight of 30-300 g/m^2,

(b2) contains 50-95% by weight of a contact adhesive,

(b3) contains a compound of Formula I in a concentration of 5-40 percent by weight based on the total weight of the polymer matrix; and

(c) delivers the compound Formula I with a steady flux rate of at least 4 $\mu g/cm^2$/hour through the human skin over a time period of at least 24 hours.

42. (previously presented) A device of claim 31 wherein the device exhibits a base area of a maximum of 40 cm, and the loading of the active ingredient of the self-adhesive polymer matrix amounts to 7-30 percent by weight.

43. (previously presented) A device of claim 31 wherein the device can transport a compound of the general Formula I in a dose of at least 3 mg per day over at least 24 hours at a constant flux rate through the human skin.

44. (previously presented) A device of claim 31 wherein the device comprises an adhesive matrix containing an active ingredient (1), a backing being impermeable and inert for the constituents of the adhesive matrix (2), and a protective layer detachable immediately before use (3).

45. (previously presented) A device for the transdermal delivery of the free base of (R)-2-[3-(1,1-diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate over a time period of at least 24 hours at a constant flux rate of at least 4 $\mu g/cm^2$/hour.

46.-67. (canceled)